China’s pharmaceutical industry is navigating two powerful currents: an aggressive pivot toward innovative “first-in-class” drugs at home, and intensifying U.S. regulatory scrutiny of Chinese biotech deals abroad. On July 3, Caixin published twin reports detailing both dynamics — and together, they paint a picture of a sector that foreign investors, partners, and competitors cannot afford to ignore.
Inside China’s Innovation Pivot
For two decades, China’s pharma sector was synonymous with generics and active pharmaceutical ingredients (APIs). That era is ending. Caixin reports that Chinese drug developers filed 98 “first-in-class” drug applications in 2025 — up from just 12 in 2020. First-in-class drugs target novel biological mechanisms rather than copying existing therapies, putting Chinese firms in direct competition with Western pharmaceutical innovators for the first time.
The shift is driven by three forces. Regulatory reform: China’s Center for Drug Evaluation (CDE) has accelerated review timelines for innovative drugs to 60 working days for priority review — faster than the FDA’s 6-month priority track. Capital availability: Venture capital investment in Chinese biotech reached $8.2 billion in 2025, according to Caixin, with the STAR Board and Hong Kong Stock Exchange’s Chapter 18A providing IPO exits for pre-revenue biotech firms. Talent回流 (huíliú, return flow): An estimated 2,500 Chinese-born PhD researchers with U.S. or European pharma experience have returned to China since 2020, building R&D teams that now rival mid-tier Western biotech firms.
The results are showing up in deal flow. Chinese biotech firms signed 47 out-licensing deals with global pharmaceutical companies in the first half of 2026, totaling $18.3 billion in upfront and milestone payments. The largest deals clustered in oncology (CAR-T and antibody-drug conjugates), metabolic diseases (GLP-1 follow-on therapies), and central nervous system disorders.
The U.S. Regulatory Headwind
At the same time, the U.S. is tightening oversight of Chinese biotech investments. Caixin’s deep-dive report notes that the BIOSECURE Act — which restricts U.S. federal funding from flowing to certain China-linked biotech companies — has reshaped deal structures even before full implementation. Foreign buyers are now demanding Chinese sellers accept lower valuations (15-25% discounts compared to 2024 levels), greater contractual protections around IP ownership, and “decoupling clauses” that allow termination if U.S. regulatory risk materializes.
The scrutiny extends beyond legislation. The Committee on Foreign Investment in the United States (CFIUS) reviewed 37 Chinese biotech investments in 2025, up from 8 in 2022. Several deals involving gene sequencing data or U.S. patient health information were blocked or restructured. Chinese pharmaceutical companies entering U.S. clinical trials now routinely face FDA requests for additional manufacturing site inspections and data integrity verification — requirements that add 6-9 months to approval timelines and $3-5 million in compliance costs per drug candidate.
Caixin reports that some Chinese biotech firms are adapting by building U.S.-based subsidiaries with independent management and segregated data systems. WuXi Biologics, for example, has invested $200 million in a Massachusetts manufacturing facility that operates under U.S. governance and data protocols. Other firms are pivoting toward European and Southeast Asian markets, where regulatory barriers are lower but commercial opportunities are smaller.
The Market Opportunity: By the Numbers
China’s total pharmaceutical market reached 2.3 trillion yuan ($320 billion) in 2025, growing at 6.8% year-on-year. Innovative drugs — those with new molecular entities — now account for 28% of total pharma sales, up from 11% in 2020. Hospital procurement data shows that domestically developed innovative drugs captured 34% of new prescriptions in Tier 1 cities in Q1 2026, versus 22% for imported innovative drugs from multinational companies.
For foreign pharmaceutical companies, the changing landscape demands a strategy rethink. The old model — import, register, distribute through a joint venture — is losing ground to Chinese innovators who are faster, cheaper, and increasingly credible on the global stage. Merck, AstraZeneca, and Roche have all expanded their China R&D centers in 2025-2026, shifting from “China for China” to “China for global” strategies that treat their Chinese labs as sources of global pipeline candidates.
As we explored in our regional investment guide, Beijing, Shanghai’s Zhangjiang Hi-Tech Park, and Suzhou’s BioBay have emerged as the three dominant biotech clusters. Beijing’s Zhongguancun Life Science Park alone hosts 487 biotech companies and generated 23 IND (Investigational New Drug) filings in 2025. Shanghai’s Zhangjiang hosts 14 of the top 20 Chinese innovative drug developers by pipeline size.
What You Should Do
Whether you are a pharmaceutical multinational, a medical device company, a healthcare investor, or a service provider to the life sciences sector, these developments demand action:
- If you are a drug developer: Evaluate Chinese biotech partners for out-licensing opportunities — but build U.S. regulatory risk into your deal terms. The discount that Chinese sellers now accept (15-25%) reflects genuine regulatory uncertainty, not just negotiating leverage.
- If you are an investor: Chinese biotech remains one of the few sectors where pre-revenue companies can access public markets through the STAR Board and HKEX Chapter 18A. But pipeline quality varies enormously. Focus on companies with at least one Phase II asset and a U.S. or European clinical trial presence.
- If you are a medical device company: China’s device registration reform now treats innovative devices similarly to innovative drugs — with priority review and conditional approval pathways. China Briefing separately reported that Beijing is emerging as a premier location for medical device investment, with the Beijing Municipal Medical Products Administration processing device registrations 40% faster than the national average.
- If you supply services to pharma: CRO (contract research organization) and CDMO (contract development and manufacturing organization) demand in China is surging, but competition is brutal. The talent gap we covered in our recent analysis of China’s hard tech talent market applies equally to biotech — senior R&D leaders now command salaries of 2-4 million yuan annually, comparable to U.S. benchmarks.
The China pharma story in 2026 is not a simple narrative of “rise” or “risk.” It is a sector in transformation — innovative, well-capitalized, and globally ambitious — but navigating regulatory headwinds that will separate the globally credible players from the domestically constrained ones. The winners will be the companies that build for both markets simultaneously.
The number to remember: $18.3 billion. That is the total value of out-licensing deals Chinese biotech firms signed with global pharma companies in H1 2026 alone. It is 40% higher than the same period in 2025 — and it is the clearest signal yet that China’s drug developers have graduated from followers to partners.
— China Gateway 360 —
Remote China market entry support, built around execution.
